American Journal of Advanced Drug Delivery Open Access

  • ISSN: 2321-547X
  • Journal h-index: 22
  • Journal CiteScore: 9.36
  • Journal Impact Factor: 5.76
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days

Subhrajit Bhattacharya

Subhrajit Bhattacharya
Rollins Research Center, Emory University, Atlanta, GA, USA


My personal interest in neuroscience stems from the belief that only a fraction of the ?brain story? has been read so far. A plethora of scientific discoveries are needed to get a better understanding of complex neural networks specifically in the field of synaptic plasticity and how it helps memories to be formed and stored. Supported by a strong training in molecular neuroscience in my masters, this interest grew into a long-term goal to become a neuroscientist and study how receptors in neurons play a major role in memory processing. The doctoral project I worked on fits into my long-term objectives, and dealt with how fear memories are reconsolidated through Glutamate receptor trafficking. We opined that reconsolidation and Glutamate receptor waves in neurons are mediated by dissociation between LTP and LTD post-retrieval. My training under Dr. Vishnu Suppiramaniam?s supervision in electrophysiology combined with behavioral neuropsychology with Dr. Martha Escobar, has given me the opportunities to integrate two fields with common roots. My long-term career goal is to pursue active research and teaching as a research faculty after a stint of rigorous post-doctoral training. I see myself in future as an established neuroscientist working for the betterment of science and technology in this ?yet-to-be- elucidated? field. My experiences from the post-doctoral program at Emory University includes extensive training in the field of synaptic mechanisms of Glutamate receptor subtype mediated activities and intense electrophysiology aided drug development of NMDAR subtype selective compounds. Besides working on NMDARs, I have worked on multiple other projects involving AMPAR and its novel auxiliary units, signaling in different parts of the thalamus in Parkinsonian models, rare human mutations affecting pediatric epilepsy and chanelopathies.